Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25215552 | 0.84 | ADRA1D (0.49) | SUV39H2 | |
| SCHEMBL25271320 | 0.84 | ADRA1D (0.49) | SUV39H2 | |
| SCHEMBL25600268 | 0.83 | S100B (0.44) | TSHRLMNANPSR1HPGDALDH1A1 | |
| SCHEMBL30039825 | 0.76 | LMNA (0.49) | MEN1LMNAKMT2ANPSR1USP2 | |
| SCHEMBL25231660 | 0.75 | SMN1; SMN2 (0.43) | HTR2ATSHRMEN1LMNAKMT2A | |
| SCHEMBL25600235 | 0.74 | CTSC (0.47) | — | |
| SCHEMBL25599594 | 0.74 | ALDH1A1 (0.47) | TSHRLMNAL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25219479 | 0.73 | HCRTR1 (0.37) | KMT2AEHMT2 | |
| SCHEMBL25261654 | 0.73 | HCRTR1 (0.37) | KMT2AEHMT2 | |
| SCHEMBL17678213 | 0.72 | NPC1 (0.48) | TSHRMEN1LMNAKMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | HTR2A 1786/4885TSHR 3548/4885SUV39H2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.